Top Markets
#1 Helium Helium +47.22%
#2 Pons Pons +39.28%
#3 TENDIES TENDIES +24.70%
#4 pipedog pipedog +23.35%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.84%
#7 Bounce Bounce +17.09%
#8 Songbird Songbird +11.97%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +10.49%
#10 OSK OSK +10.30%
Coin of the day
Helium Helium
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
शेयरों में रैंक #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
शेयर मूल्य
$9.50
अंतिम समन्वयन: 2025-01-08
मार्केट कैप
$819.52M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Poseida Therapeutics, Inc. (PSTX)

श्रेणी

Healthcare
Poseida Therapeutics, Inc. (PSTX) के लिए बकाया शेयरों की संख्या
September 2024 की स्थिति में बकाया शेयरों की संख्या: 97.16M
Poseida Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी के वर्तमान बकाया शेयरों की संख्या 97.16M है। December 2022 के अंत में कंपनी के पास 71.91M बकाया शेयर थे। बकाया शेयरों की संख्या आमतौर पर शेयर स्प्लिट्स और शेयर बायबैक से प्रभावित होती है।
Poseida Therapeutics, Inc. (PSTX) के लिए 2016 से 2026 तक बकाया शेयरों का इतिहास
प्रत्येक वर्ष के अंत में बकाया शेयर
वर्ष बकाया शेयर परिवर्तन
2026 (TTM) 97.16M 7.73%
2023 90.19M 25.41%
2022 71.91M 15.66%
2021 62.18M 6.47%
2020 58.40M 46.98%
2019 39.73M 10.59%
2018 35.93M -9.57%
2017 39.73M -33.01%
2016 59.32M 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए बकाया शेयर
कंपनी बकाया शेयर अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 161.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -36.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 392.91%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 307.57%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH